Trial Profile
An open and one-armed exploration of Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Non-small Cell Lung
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 23 Jun 2017
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary) ; Docetaxel
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 23 Jun 2017 New trial record